Rapid Uptake of Skyrizi Protects the AbbVie Portfolio in Plaque Psoriasis as Humira Share Continues to Dwindle in the First-Line Setting
Momentum builds for the newest market entrant as use in biologic-naïve psoriasis patients surpasses all alternative mechanism of action biologics within its first year of launching, according to patient level data collected by Spherix Global Insights EXTON, Pa., June 9, 2020 /PRNewswire/ — The 2020 audit included in Spherix’s RealWorld Dynamix™: Biologic/Small Molecule New Starts […]
Newest Oral DMTs Haven’t Yet Made a Big Impact in the MS World
From: MDedge Neurology By: Bruce Jancin The three oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) approved last year in the United States haven’t made a big splash in the marketplace. So far, it’s more like a ripple, according to a study of neurologists’ prescribing patterns. “The recently approved therapies will initially be niched as […]
Less Than One Year Post Launch, AbbVie’s Rinvoq Disrupts the Rheumatoid Arthritis Treatment Landscape, While a Rich Pipeline Waits in the Wings
The newest market entrant and possibly next autoimmune blockbuster has had an impressive launch so far, according to Spherix Global Insights EXTON, Pa., June 4, 2020 / PR Newswire / –The latest quarterly report included in Spherix’s RealTime Dynamix: Rheumatoid Arthritis (US) service captures the responses of 105 rheumatologists surveyed in May 2020 and highlights […]
Despite Increased Competition from the Recent Launch of Janssen’s Stelara, Takeda’s Entyvio Continues to Shine as a Leading Ulcerative Colitis Treatment
Use of Entyvio will only be further bolstered if/when the brand’s new subcutaneous formulation receives the FDA green light, according to a recently published study by Spherix Global Insights EXTON, Pa., June 1, 2020 /PRNewswire/ — Takeda’s Entyvio has proven to be one of the leading go-to options for the treatment of ulcerative colitis (UC), even […]
Specialty Physicians Report Signs of Rebound from COVID-19, but Are Pessimistic About Reopening Without a Resurgence
According to feedback from the sixth wave of COVID-19 impact tracking, Spherix Global Insights finds that patient volumes remain severely depressed and physicians are worried about patients with non-COVID conditions being able to access care EXTON, Pa., May 27, 2020 / PRNewswire / – Since the end of March, Spherix Global Insights has been tracking […]
Amid the COVID-19 Pandemic, Neurologists in Canada Report Pulling Back from EMD Serono’s Mavenclad and Sanofi Genzyme’s Lemtrada, While Roche’s Ocrevus Stalls, According to Spherix Global Insights
Use in treatment-naïve patients drives recent growth of Biogen’s Tecfidera and Genzyme’s Aubagio in Canada, as reported switch share has remained flat over the past year – reflecting the continued shift in using established oral agents earlier in the multiple sclerosis treatment algorithm EXTON, Pa., May 27, 2020 /PRNewswire/ — The COVID-19 pandemic has (at […]
Survey Finds Cimzia Prescriptions for nr-axSpA on the Rise in US
From: Ankylosing Spondylitis News By: Patricia Inacio, PhD. According to Spherix Global Insights’ survey, which was conducted in March, the main barriers to prescribing Cimzia for nr-axSpA in the U.S. were insurance and cost issues. However, the number of rheumatologists citing these as obstacles has significantly decreased year after year, which highlights the potential widespread […]
Switching Patterns Among Relapsing-Remitting Multiple Sclerosis: Genentech’s Ocrevus on the Rise, Biogen’s Tecfidera Declines, and Teva’s Copaxone Remains Strong, According to Spherix Global Insights
Is there trouble in paradise for Genentech? US neurologist reevaluation of Ocrevus in PPMS patients, along with competitive pressure from Bristol Myers Squibb’s Zeposia, Novartis’ ofatumumab, and Janssen’s ponesimod, will further test the resiliency of the current leaders in the switch segment EXTON, Pa., April 30, 2020/PRNewswire/ — Genentech’s Ocrevus, Teva’s Copaxone, and Biogen’s Tecfidera […]
UCB’s Cimzia is Making Inroads in the Treatment of Axial Disease, with Significant Uptake in Non-Radiographic Axial Spondyloarthritis and a Positive Treatment Halo in Ankylosing Spondylitis
In AS, the IL-17 inhibitors are beginning to challenge the leading TNF inhibitors, but rheumatologists struggle to differentiate Novartis’ Cosentyx and Eli Lilly’s Taltz, according to a new report by Spherix Global Insights EXTON, Pa., April 29, 2020 /PRNewswire/ — The recent approval of UCB’s TNF inhibitor, Cimzia, for the treatment of non-radiographic axial spondyloarthritis […]
Spherix Global Insights Donates $50,000 To Support Healthcare Workers and Vulnerable Patient Populations Battling the COVID-19 Pandemic
EXTON, Pa., April 20, 2020 /PRNewswire/ ― Spherix Global Insights, the leading independent market intelligence firm in specialty biopharma markets, is giving back to the community with a donation of $50,000 across local and national healthcare organizations. Recent research conducted by the firm documented the massive toll COVID-19 is taking on physician practices and the […]